Wells Fargo Starts Lion Biotechnologies (LBIO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts LBIO Hot Sheet
Price: $6.95 --0%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Wells Fargo initiates coverage on Lion Biotechnologies (NASDAQ: LBIO) with a Outperform rating.
For an analyst ratings summary and ratings history on Lion Biotechnologies click here. For more ratings news on Lion Biotechnologies click here.
Shares of Lion Biotechnologies closed at $7.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi initiates ATI Inc. coverage with Buy rating, $229 target
- Morgan Stanley Starts Elevate Campuses Ltd (ELEVATE:IN) at Overweight
- CLSA Starts Busy Ming Group (1768:HK) at Outperform (2)
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
